Low-dose Aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma

Niesvizky R, Martínez-Baños D, Jalbrzikowski J, Christos P, Furst J, De Sancho M, Mark T, Pearse R, Mazumdar M, Zafar F, Pekle K, Leonard J, Jayabalan D, Coleman M.

Center of Excellence for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, Department of Medicine.

Multiple myeloma (MM) patients have a propensity for thromboembolic events (TE), and treatment with thalidomide/dexamethasone or lenalidomide/dexamethasone increases this risk. This report describes the use of low-dose aspirin (81 mg) as primary thromboprophylaxis in three series of MM patients receiving thalidomide or lenalidomide with other drugs. In the first regimen (clarithromycin, thalidomide, dexamethasone), initiation of low-dose aspirin negated the occurrence of any further TE. In a second study, prophylactic aspirin given with thalidomide/dexamethasone resulted in a rate of TE similar to that seen with dexamethasone alone (without aspirin). A third study (n = 72) evaluated thrombosis rates with aspirin and a lenalidomide-containing regimen (clarithromycin, lenalidomide, dexamethasone). Of nine occurrences of thromboembolism, five were associated with aspirin interruption or poor compliance. Low-dose aspirin appears to reduce the incidence of thrombosis with these regimens. Routine use of aspirin as antithrombotic prophylaxis in MM patients receiving immunomodulatory drugs with corticosteroids is warranted.

PMID: 18067007 [PubMed - in process]

Genmab starts Phase I/II HuMax-CD38 trial for Myeloma

Genmab (GEN.CO) started a Phase I/II safety and dose finding study of its human antibody HuMax-CD38 for the treatment of multiple myeloma, a plasma cell disorder.

The study will include up to 122 patients who are relapsed or resistant to at least two different prior treatments. HuMax-CD38 is an antibody that targets the CD38 molecule on the surface of multiple myeloma tumour cells.